Rating: Neutral (Neutral) | Target Price: RMB 80–120 | Current Price: RMB 97.65 (Close 2026-07-21)
Margin of Safety: -18% | Time Horizon: 12–18 Months | Confidence: 0.55
Orbbec is one of the leaders in the global 3D vision perception sector, standing at the starting point of structural demand expansion driven by humanoid robots/embodied intelligence. FY2025 achieved its first annual profit since listing, with full-stack proprietary technology and binding of top-tier customers forming competitive moats. However, at the current price of RMB 97.65 (market cap ~RMB 40.2 billion), the FY2027E P/E is approximately 72x, which is at the upper end of the fair value range. This is combined with multiple short-term pressures: substantial controlling shareholder reduction (approximately 5.75 million shares / RMB 720 million), a sharp drop in FY2026Q1 revenue growth to +6.19%, and negative operating cash flow. The reward-risk profile is slightly unfavorable. It is recommended to wait for the 2026 semi-annual report and Q3 robot order signals before making a directional judgment.
Key Evidence:
Counter-argument: The industry is still in the early standardization phase – the number of 3D modules required per humanoid robot (2-4 vs. optimistic industry expectations of 3-6) has not yet converged; GGII's 2022 penetration data is already 4 years old without updated third-party verification. More importantly, sensor modules inevitably decline in price with scale effects – as a component supplier, Orbbec faces ASP downside risk that may partially offset shipment growth (refer to the LiDAR industry's historical "volume up, profit down" phenomenon in 2021-2022). Demand direction is certain, but the slope and profit elasticity require sequential quarterly validation.
Key Evidence:
Counter-argument: ① The 71% market share is from 2022; over 4 years, giants like Huawei have entered, and Intel RealSense accelerated its independent layout after 2025, so the landscape may have changed. ② Top-5 customer concentration is 63.92%, of which Ant Group related parties account for 26.84% – the fairness of related-party transaction prices is difficult to verify independently, and core customers like Unitree have incentives to introduce a second source or self-develop (Unitree's IPO prospectus lists "vision perception" as a core competitiveness). ③ The "six technology roadmaps" of full-stack self-development cover a wide range, but could result in "jack of all trades, master of none" – not necessarily achieving extreme leadership in any single roadmap.
Key Evidence:
Key Controversy: FY2025 non-recurring gains (government grants RMB 27.6 million + wealth management income RMB 38.03 million, etc.) totaled RMB 57.03 million, accounting for 44.6% of attributable net profit. Recurring net profit was only RMB 70.88 million, so the quality of the "profit turnaround" based on this needs discounted assessment. The Q1 2026 recurring +531% YoY increase was built on an extremely low base of RMB 3.45 million in Q1 2025. The R&D expense ratio rebounded to 26.36% in Q1 2026, inconsistent with the direction of "continuous operating leverage improvement". The profit inflection point is preliminarily established, but the term "established" requires at least 1-2 more quarters of revenue growth and OCF validation.
Key Evidence:
Core Tension in Valuation Logic: The current price implies market expectations – FY2027E net profit must reach about RMB 500 million, and recurring net profit margin must jump from FY2025's 7.5% to about 18-22%. This means a leap in recurring net profit from RMB 71 million to about RMB 400-500 million within two years (about 6-7 times), requiring revenue to grow from RMB 940 million to RMB 2.5-3.0 billion (CAGR ~65%) and continued compression of expense ratios. This is achievable under the assumption that humanoid robots ramp up as expected and ASP does not decline, but there is very little room for error under real pressures such as intensified competition, ASP decline, and customer self-development/dual sourcing. Three-tier value analysis: EPV (zero growth) is only about RMB 3.10 per share – the current price is almost entirely supported by growth options; if the growth narrative is damaged, downside space is enormous.
Key Evidence:
The information content of these signals should not be underestimated: ① The controlling shareholder's first large-scale reduction since IPO coincides exactly with the "profit inflection point established" and "humanoid robot explosion eve" – if the outlook is indeed bright, why concentrate cash-out now? ② Q1 2026 is the first full quarter after FY2025's +66.66% growth; if the slowdown to +6.19% continues into the second half, sell-side FY2026E revenue growth forecasts of +56-82% will be falsified, requiring a restructuring of the entire valuation framework. ③ Operating cash flow of -RMB 117 million means that "profit" is currently just paper profit, and actual operations are consuming cash. These signals do not directly negate the long-term logic of humanoid robots, but their combined severity requires investors to maintain a higher validation threshold for the "inflection point story" – at least 1-2 quarters of resurging revenue growth and OCF turning positive to hedge against this.
| Indicator | FY2023 | FY2024 | FY2025 | 2026Q1 |
|---|---|---|---|---|
| Revenue (RMB 100 million) | 3.60 | 5.64 | 9.41 | 2.03 |
| Revenue YoY | — | +56.79% | +66.66% | +6.19% |
| Attributable Net Profit (RMB 100 million) | -2.76 | -0.63 | 1.28 | 0.31 |
| Recurring Net Profit (RMB 100 million) | -2.90 | -1.12 | 0.71 | 0.22 |
| Gross Margin | — | — | 43.54% | — |
| Net Margin | — | — | 13.59% | 15.28% |
| Operating Cash Flow (RMB 100 million) | -1.60 | -0.86 | 0.83 | -1.17 |
| Free Cash Flow (RMB 100 million) | — | — | 0.20 | — |
| Cash and Cash Equivalents (RMB 100 million) | — | — | — | 6.60 |
| Interest-bearing Debt (RMB 100 million) | — | — | — | 1.14 |
| Debt-to-Asset Ratio | — | — | 12.27% | — |
Reasons for Changes in Indicators:
2026Q1 presents a divergent pattern of "profit improvement, revenue slowdown, and cash flow deterioration":
Judgment: Q1 profit improvement direction is correct, but the combination of the sharp revenue slowdown and OCF deterioration significantly reduces the credibility of a "firmly established profit inflection point." The 2026 semi-annual report (expected around August 22) will be a key validation window.
Orbbec operates a Fabless chip design + module solution integration asset-light model. Core value lies in self-developed depth engine chips (MX series), photosensitive chips (LS635), and algorithms; hardware manufacturing and packaging are outsourced. The company positions itself as a "robot and AI vision industry platform." The revenue model is project/product-based sales (not subscription), so revenue is not inherently recurring. The addressable market covers three segments: robotics (54.78% of revenue), biometrics (41.75%), and industrial 3D scanning (2.76%).
| Indicator | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| OCF/Net Profit | 0.58 | 1.37 | 0.65 |
| FCF/Net Profit | — | — | 0.15 |
ROIC (attributable net profit / opening net equity) was approximately 4.4% (FY2025), far below WACC (~10-12%). The company is in the early stage of a profit inflection point; current ROIC is not representative, but indicates that current profit is insufficient to cover capital cost – a typical feature of growth stocks at the early inflection.
CapEx/Depreciation ≈ 1.27 (FY2025: CapEx RMB 63.12 million vs Depreciation & Amortization total ~RMB 49.84 million). CapEx exceeds depreciation, but mainly directed to Shunde factory construction (Construction-in-progress FY2025 -99.67% YoY, Fixed assets +39.66%, due to factory transfer-to-assets) – during capacity build-out period, CapEx above depreciation is a temporary phenomenon rather than a structural "capital black hole." After the factory is operational and capacity utilization ramps up, CapEx/Depreciation is expected to fall below 1.
| Commitment | Actual | Judgment |
|---|---|---|
| FY2024 Annual Report stated "Focus on rigid demand downstream, achieve profitability as soon as possible" | FY2025 achieved attributable net profit RMB 128 million, recurring RMB 71 million, turned profitable | ✅ Fulfilled |
| 2026 Quality Improvement & Efficiency Enhancement Action Plan, focus on robot/AI vision penetration | 2026Q1 robot revenue YoY 3x, but overall revenue growth only +6.19% – direction correct but magnitude below expectation | ⚠️ Partially fulfilled |
Overall judgment: Management is pragmatic, but guidance is qualitative and lacks specific numbers. IR response style is standardized, avoiding sensitive issues (customers/performance guidance) citing "disclosure standards not met" – information transparency is average.
Judgment: Shareholder friendliness is neutral-to-negative – active buybacks offset by controlling shareholder reduction; no dividends in foreseeable future due to accumulated losses; controlling shareholder's first large-scale reduction since IPO occurring at the "inflection point established" timing is a slightly negative signal.
| Segment | Revenue Share | Gross Margin | YoY Growth | Business Logic |
|---|---|---|---|---|
| AIoT (incl. Robotics/3D Scanning) | 54.78% | 56.72% | +71.78% | Robot vision sensors + consumer-grade 3D scanners, highest gross margin, main profit driver and growth engine |
| Biometrics (Payment/Medical Verification) | 41.75% | 24.95% | +68.98% | Face payment terminals + "Tap-to-Pay" devices, high volume but low margin, contributing revenue growth |
| Industrial 3D Scanning | 2.76% | 66.84% | -2.47% | High margin but very small scale; subsidiary Xin Tuo Xi'an operations in start-up phase, not a major driver in near term |
Primary profit driver: AIoT (incl. Robotics)
The AIoT segment, with a 54.78% revenue share and the highest gross margin of 56.72%, contributes approximately 70% of gross profit (54.78% × 56.72% / 43.54% ≈ 71%). Although biometrics has a 41.75% revenue share, its gross margin is only 24.95%, limiting profit contribution—the company's growth "quality" is highly concentrated in the robotics track.
Gross margin structure divergence: AIoT (56.72%) vs Biometrics (24.95%)—a gap of over 30 percentage points. The former reflects pricing power from technical barriers + scenario customization; the latter results from standardized modules + large customer price pressure. This structural difference implies: for every 10ppt increase in robotics share, blended gross margin rises by approximately 3ppt—this is the core driver of the company's margin improvement.
| Item | Severity | Evidence |
|---|---|---|
| All R&D expenses expensed (capitalization ratio 0%) | Low | FY2025 R&D spending 203M RMB, capitalization 0—conservative but depresses current profit; STAR Market peers often have some capitalization ratio |
| Metric | Multi-period Trend | Consistency with Management Explanation | Assessment |
|---|---|---|---|
| Revenue growth vs expense growth divergence | FY2024-2025: Revenue +56.79%/+66.66%, Selling expenses -2%/-5.89% consecutively, Admin expenses declining | Consistent—company explains as "structural resource allocation and refined expense control"; e-interaction response states no inter-period expense shifting | Consistent |
| Operating cash flow sharply turns negative | FY2023→2024→2025: OCF improved from -160M → -86M → +83M, but suddenly turned negative to -117M in 2026Q1 | Consistent—company explains as substantial increase in bill receivables collection, pending maturity at period end | Consistent, but need to watch Q2 recovery |
Overall Assessment: Based on the financial reports reviewed, no notable signs of financial engineering were found. Full expensing of R&D is conservative, not a red flag. The divergence between revenue growth and expense growth has a reasonable explanation. The main concern is the evolution of the 2026Q1 OCF plunge.
| Metric | Value | Percentile (1yr/3yr/5yr) | Notes |
|---|---|---|---|
| PE(TTM) | ~314x | 25% / 25% / 25% | Just turned profitable; earnings not representative; percentile for reference only |
| PB(MRQ) | 13.16x | 81% / — / 95% | High PB supported by growth expectations, not asset returns |
| PS(TTM) | ~42x | Limited history | High PS reflects market premium for high growth |
| FY2027E PE | ~72x | — | Based on consensus net profit of 555M |
| PEG (FY26→27E) | ~0.96x | — | Based on FY2026→2027E net profit growth of 75% |
The current price implies the market believes: FY2027E net profit of ~500M (corresponding to PE 80x), with non-recurring net margin rising from 7.5% in FY2025 to ~18-22%. Two-way test:
| Layer | Per Share Value | % of Current Price | Description |
|---|---|---|---|
| Asset Value (Liquidation Floor) | ~7.24 RMB | 7.4% | BVPS at FY2025 end |
| EPV (Zero Growth) | ~3.10 RMB | 3.2% | TTM non-recurring EPS 0.217 RMB / WACC 11% + Net Cash 1.33 RMB |
| Growth Option | ~94.55 RMB | 96.8% | Current Price − EPV |
The current price is almost entirely supported by the growth option. EPV is only 3.10 RMB/share—current earnings are far from normalized levels after capacity ramp-up, typical of early-turnaround growth stocks. A high proportion of growth option alone does not directly equal "overvalued"—the key is whether growth should be paid for, answered by scenario analysis.
| Scenario | Probability | Fair Value Range | Key Factor | Notes |
|---|---|---|---|---|
| Bear Case | 25% | 40–55 RMB | Humanoid robot mass production significantly below expectations (global 2027 shipments <50k units), 3D vision penetration stagnant, competitors cut prices for share | Bear case floor of 40 RMB already covers more pessimistic scenario implied by Guotou Securities target price of 93.61 RMB (still "Buy" rating); our bear case assumes inflection point fails / share loss, larger downside |
| Base Case | 50% | 80–120 RMB | Humanoid robot ramps as expected (global 2027 shipments ~150k units), Orbbec benefits with 20-25% share. Ramp-up estimate: Revenue FY2025-28E CAGR ~65% (0.94→3.0→4.2B), exit year FY2028E net profit ~860M × 40-55x PE = 37-47B market cap, discounted → 80-120 RMB/share | Exit multiple anchor: current trading multiples of comparable companies that have already passed inflection point (not the company's own historical mean reversion) |
| Bull Case | 25% | 140–200 RMB | Humanoid robot shipments exceed expectations (global 2027 >250k units), 3D vision becomes standard (3-6 modules per unit), Orbbec share expands to 30%+ | FY2028E net profit >1.2B × 55-65x PE |
Odds: Current price of 97.65 RMB is near the base case midpoint (100 RMB). Upside to base case upper bound ~+23%, downside to base case lower bound ~-18%, downside to bear case midpoint ~-51%. Odds neutral-to-negative—limited upside, significant downside risk.
| Period | Revenue (Billion RMB) | Net Profit (Billion RMB) | Key Assumptions | Comparison |
|---|---|---|---|---|
| FY2026E | 1.5–1.8 | 0.26–0.35 | Robot more than doubles (Q1 already 3x), 3D scanning +50-70%, overseas +80%; Gross margin 45-48% | Sell-side consensus 317M; management no numeric guidance |
| FY2027E | 2.5–3.2 | 0.45–0.70 | Humanoid robot mass production accelerates, scale effects drive net margin to 18-22% | Sell-side consensus 555M |
Valuation Assessment: Reasonably High (fair). The company has excellent quality and is at a structural demand inflection point, but the current price has largely priced in high growth expectations for the next 2-3 years—the median sell-side target price of 95.3 RMB is even slightly below the current price. Safety margin is -18% (base case lower bound 80 RMB vs current 97.65 RMB), not extremely expensive among inflection-point growth stocks, but with little room for error. Recommend waiting for 2026Q2-Q3 performance signals (revenue growth recovery + OCF positive + continued robot order volume) before making directional allocation decisions.
The 3D vision perception industry is at an inflection point from "optional feature" to "essential standard". Global: market size ~$15B in 2025 (Yole, incl. 3D sensing modules/cameras and system solutions), expected to reach $17.2B by 2028 (CAGR ~13%). China: ~15-20B RMB in 2024 (incl. consumer/industrial/automotive), narrow sensor market ~7.6B in 2026 (LeadLeo), expected CAGR ~30% from 2023-2027.
Humanoid robot sub-track (core demand inflection driver): Each humanoid robot requires 2-4 3D vision modules (vs. traditional AGV only 1), a 2-4x jump in unit usage. Global humanoid robot market ~$2.4B in 2025 → $66B by 2032 (Fortune, CAGR 45.5%), China market may exceed 75B RMB by 2029 (Zheshang Securities). The humanoid robot 3D vision sub-track alone has a potential market of ~9.15B RMB by 2030 (Zheshang estimate). Service robot 3D vision penetration expected to rise from ~35% in 2022 to 60%+ by 2026 (GGII).
Quantification chain (demand inflection 1.8):
Upstream: Optical components (VCSEL lasers/lenses/filters), photosensitive chips (CMOS/SPAD), depth engine chips. Suppliers include Sony, Lumentum, Sunny Optical, etc., relatively mature and transparent pricing.
Midstream (Orbbec's position): 3D vision sensor module design and system integration—the core value chain link, requiring mastery of depth engine algorithms, calibration compensation, multi-sensor fusion and other system-level capabilities. Hardware assembly barriers are low, but algorithms (temperature drift compensation, point cloud processing) and scenario know-how form the core barrier. Software+algorithm premium in midstream contributes most of the industry's gross profit (reflected in 43%+ gross margin). Orbbec has moderate bargaining power with upstream (self-developed chips reduce external dependence) and relatively strong bargaining power with downstream (technical scarcity + certification stickiness leading to high customer switching costs).
Downstream: Robotics (service/humanoid/AMR), Biometrics (face payment/medical verification), AIoT (3D scanning/smart home), Consumer electronics (mobile/AR/VR), Industrial measurement, Automotive, etc.
Demand side: Three engines simultaneously exploding—① Robotics: 3D vision from "optional" to "essential"; ② 3D scanning: Consumer-grade scanners CAGR 17% 2024-2029E (CIC); ③ Face payment: "Tap-to-Pay" and other terminals continue deployment. Overall supply-demand tight—algorithm barriers limit scalable new entrants, top players' capacity utilization near full.
Competitive landscape: Globally, only about 7-8 companies have mass production capability for million-unit array 3D vision sensors (Apple, Microsoft, Sony, Intel, Samsung, Huawei, Orbbec). In service robot 3D vision, Orbbec has >71% China market share (GGII 2022). Main competitors: Intel RealSense (became independent in 2025, raised $50M), Sony (top ToF sensor upstream, 17.5% share), Sunny Optical Intelligent (backed by optical leader, extending to modules). Domestic startups (Huajie Aimei, Guangjian Technology) have huge scale gap. Triple entry barriers: Technology patents (1,967) + Customer certification (1-2 year cycle) + Mass production scale (3-5 years process accumulation).
Overall favorable direction. State Council "AI+" action promotes intelligent robots/AI terminals; "Face Recognition Technology Application Security Management Measures" (effective June 1, 2025) temporarily suppresses some face payment scenarios but benefits compliant leading companies; GB/T 45501-2025 "General Technical Requirements for 3D Vision Guidance Systems for Industrial Robots" (effective October 2025) establishes industry standards, raising technical thresholds.
| Company | Revenue Scale | Revenue Growth | Gross Margin | ROE | Positioning | Key Difference vs Orbbec |
|---|---|---|---|---|---|---|
| Orbbec | 941M (FY2025) | +66.66% | 43.54% | 4.3% | 3D Vision full-stack leader | — |
| Hikvision | ~90B | +11.8% | ~45% | 15.3% | AI Vision+Security giant | Mature profitable stage, 100x scale of Orbbec, but robot vision is marginal business |
| Sunny Optical | ~33B | +12.9% | ~18-20% | 17.2% | Mobile lens+Automotive optics leader | Upstream optical component maker extending to 3D modules; Orbbec focuses on algorithms+chips |
| Leaderdrive | ~500M | +47% | ~40% | 3.6% | Harmonic reducer leader | Similar inflection-point upstream robot component stock, but entirely different track |
| Unitree (IPO) | 1.7B (FY2025) | +335% | ~60% | ~35% | Humanoid robot OEM leader | OEM with stronger profitability than Orbbec, but different business nature |
Orbbec is a first-tier player in the global 3D vision perception field, alongside Apple, Microsoft, Sony, and Intel. It holds an absolute lead in China's service robot 3D vision sensor market (GGII 2022 >71% share). Moat sources: ① Full-stack self-developed (six technical routes + self-developed chips + 1,967 patents); ② Customer certification barriers (deeply bound with Nvidia/Apple/Microsoft/Ant Group ecosystem); ③ Mass production capability (Shunde million-unit capacity + Vietnam factory under construction). Achieved first annual profit in 2025, entering "scale and profit dual growth" phase. However, note: market share data is 4 years old, industry landscape may have changed; company's share in humanoid robot field is still being established and cannot be directly equated with its dominant position in service robots.
Rating: Neutral | Target Price 80–120 RMB | Confidence 0.55
Orbbec is a classic case of "good track, good company, not cheap stock". The structural demand logic for 3D vision in robotics/embodied intelligence era is clear. The company occupies a leading position with full-stack self-development and top customer binding. FY2025 first profit marks crossing the breakeven line. However:
This report is based on public information and financial model estimates, not investment advice. Data as of 2026-07-21.